Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

AT ELANA 841P Posterior Chamber Intraocular Lens for Correction of Aphakia Following Cataract Removal

NCT: NCT06264232 · COMPLETED

NCT IDNCT06264232
StatusCOMPLETED
Start Date2024-07-12
Completion2025-12-01
SponsorCarl Zeiss Meditec, Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

The goal of this clinical trial is to demonstrate the safety and effectiveness of the full visual range AT ELANA 841P IOL when used to treat adult patients having cataract surgery. Subjects will be randomly selected to receive a pair of IOLs, either the AT ELANA 841P or CT LUCIA 621P lens design. All patients will undergo surgery in both eyes, and they will receive follow up care for up to 6-months. During this time, all patients will undergo thorough eye exams at every study visit and complete questionnaires about their quality of vision post-surgery.

Frequently Asked Questions

What is AT ELANA 841P Posterior Chamber Intraocular Lens for Correction of Aphakia Following Cataract Removal?

AT ELANA 841P Posterior Chamber Intraocular Lens for Correction of Aphakia Following Cataract Removal is a clinical trial registered under NCT06264232. Current status: COMPLETED.

What is the status of NCT06264232?

The current status of NCT06264232 (AT ELANA 841P Posterior Chamber Intraocular Lens for Correction of Aphakia Following Cataract Removal) is: COMPLETED.

When did AT ELANA 841P Posterior Chamber Intraocular Lens for Correction of Aphakia Following Cataract Removal start?

AT ELANA 841P Posterior Chamber Intraocular Lens for Correction of Aphakia Following Cataract Removal started on 2024-07-12.

Related Devices

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.